文献速递前列腺癌

前列腺癌治愈性治疗后生化复发的预后价值:系统综述

Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
PubMed 文献 · Eur Urol · 2018-10-17

该系统综述纳入77项研究,评估非转移性前列腺癌治愈性治疗后生化复发(BCR)对肿瘤学结局的影响。BCR与较差的生存率相关,但该效应似乎仅限于具有特定临床风险因素的患者亚组,如根治性前列腺切除术后短PSA倍增时间(PSA-DT)和高最终Gleason评分,或根治性放疗后短生化失败间隔(IBF)和高穿刺Gleason评分。这些因素可能构成新的BCR风险分层(欧洲泌尿外科学会BCR风险组)的基础,尚需正式验证。

要点

  • BCR与较差生存相关,但仅局限于具有特定风险因素的患者亚组。
  • RP后短PSA-DT和高最终Gleason评分是负向预后因素。
  • RT后短IBF和高穿刺Gleason评分是负向预后因素。

核心结论

  • BCR对生存有影响,但该效应似乎仅限于具有特定临床风险因素的患者亚组。
  • RP后短PSA-DT和高最终Gleason评分,以及RT后短IBF和高穿刺Gleason评分,是对生存有负面影响的主要因素。
  • 这些因素可能构成新的BCR风险分层(欧洲泌尿外科学会BCR风险组)的基础,需要正式验证。

研究设计与样本

  • 系统综述,检索Medline、Medline In-Process、Embase和Cochrane Central Register of Controlled Trials。
  • 共纳入77项研究进行分析;其中14项研究(招募20 406例患者)回答目标1。
  • 目标2由71项研究回答,分别涉及29 057例、11 301例和4272例接受RP、RT和混合人群的患者。
  • 纳入标准:目标1为比较RP或RT后有无BCR患者生存结局的前瞻性和回顾性研究;目标2为至少100名参与者且报告BCR患者预后临床和肿瘤特征的研究。
  • 采用Quality in Prognosis Studies工具进行偏倚风险和混杂评估,并进行叙述性综合和荟萃分析。

主要发现

  • BCR与较差的生存率相关,主要见于RP后短PSA-DT和高最终Gleason评分,或RT后短IBF和高穿刺Gleason评分的患者。
  • 研究参与、混杂因素和统计分析方面偏倚风险低;多数研究的失访偏倚、预后和结局测量未明确报告。

临床怎么用

  • 对于治愈性治疗后出现BCR的前列腺癌患者,应评估PSA-DT、Gleason评分和IBF等风险因素以进行风险分层。
  • BCR风险分层可能基于RP后短PSA-DT和高最终Gleason评分,以及RT后短IBF和高穿刺Gleason评分。

局限性

  • 多数研究的失访偏倚、预后和结局测量未明确报告。
  • 提出的BCR风险分层(欧洲泌尿外科学会BCR风险组)需要正式验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: In men with prostate cancer (PCa) treated with curative intent, controversy exists regarding the impact of biochemical recurrence (BCR) on oncological outcomes. OBJECTIVE: To perform a systematic review of the existing literature on BCR after treatment with curative intent for nonmetastatic PCa. Objective 1 is to investigate whether oncological outcomes differ between patients with or without BCR. Objective 2 is to study which clinical factors and tumor features in patients with BCR have an independent prognostic impact on oncological outcomes. EVIDENCE ACQUISITION: Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. For objective 1, prospective and retrospective studies comparing survival outcomes of patients with or without BCR following radical prostatectomy (RP) or radical radiotherapy (RT) were included. For objective 2, all studies with at least 100 participants and reporting on prognostic patient and tumor characteristics in patients with BCR were included. Risk-of-bias and confounding assessments were performed according to the Quality in Prognosis Studies tool. Both a narrative synthesis and a meta-analysis were undertaken. EVIDENCE SYNTHESIS: Overall, 77 studies were included for analysis, of which 14 addressed objective 1, recruiting 20 406 patients. Objective 2 was addressed by 71 studies with 29 057, 11 301, and 4272 patients undergoing RP, RT, and a mixed population (mix of patients undergoing RP or RT as primary treatment), respectively. There was a low risk of bias for study participation, confounders, and statistical analysis. For most studies, attrition bias, and prognostic and outcome measurements were not clearly reported. BCR was associated with worse survival rates, mainly in patients with short prostate-specific antigen doubling time (PSA-DT) and a high final Gleason score after RP, or a short interval to biochemical failure (IBF) after RT and a high biopsy Gleason score. CONCLUSIONS: BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors. Short PSA-DT and a high final Gleason score after RP, and a short IBF after RT and a high biopsy Gleason score are the main factors that have a negative impact on survival. These factors may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally. PATIENT SUMMARY: This review looks at the risk of death in men who shows rising prostate-specific antigen (PSA) in the blood test performed after curative surgery or radiotherapy. For many men, rising PSA does not mean that they are at a high risk of death from prostate cancer in the longer term. Men with PSA that rises shortly after they were treated with radiotherapy or rapidly rising PSA after surgery and a high tumor grade for both treatment modalities are at the highest risk of death. These factors may form the basis of new risk stratification (European Association of Urology biochemical recurrence Risk Groups), which needs to be validated formally.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Van den Broeck T, van den Bergh RCN, Arfi N, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2018. PMID: 30342843. doi:10.1016/j.eururo.2018.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。